Cosmos Health Inc. (COSM): Nasdaq/NYSE listing notice — Cosmos Health receives Nasdaq reprimand for prior shareholder approval violation; matter closed

Cosmos Health Inc.

Nasdaq issued a Letter of Reprimand on Sept 27, 2023, for failing to obtain prior shareholder approval for October 2022 public offering.
Offering involved units of common stock and warrants at a discount exceeding Nasdaq minimum price rules.
Company stated violation was inadvertent; 98% of votes at Dec 2022 meeting were affirmative had approval been sought.
Shareholder ratification obtained at Sept 18, 2023 annual meeting; no further action required.
Nasdaq noted no prior pattern of non-compliance; matter considered closed.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cosmos Health Inc. received a nasdaq other notice regarding other (rules 5810(c)(4)).

Exchange: nasdaq
Rules: 5810(c)(4)

Exact text from the filing

September 27, 2023, Cosmos Health Inc. (the “Company”) received a Letter of Reprimand from the Nasdaq Stock Market in accordance with Listing Rule 5810(c)(4). Nasdaq had previously determined that the Company had not obtained prior shareholder approval for the October 2022 best-efforts public offering involving the issuance of 20% or more of the outstanding shares at less than the minimum price. Because the offering consisted of Units of common stock, Series A Warrants and Series B Warrants it was necessary to allocate a value to the warrants which resulted in the Units being sold at a great

View on SEC.gov

Browse all listing & compliance notices →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-007315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.